News | Cardiac Diagnostics | February 09, 2016

New Study Explores Impact of Worksite-based Lifestyle Intervention on Cardiovascular Risk

Study by Mount Sinai Heart Institute to investigate how worksite-based lifestyle intervention and imaging techniques can reduce the risk of cardiovascular disease

Mount Sinai Heart, TANSNIP-PESA study, worksite lifestyle intervention, cardiovascular risk

February 9, 2016 — Mount Sinai Heart is undertaking a three-year study to determine whether a workplace-based lifestyle intervention, accompanied by imaging data, will reduce the prevalence of cardiovascular (CV) disease risk factors related to lifestyle.

The study, known as TANSNIP-PESA, will be led by Valentin Fuster, M.D., Ph.D., director of Mount Sinai Heart and physician-in-chief of The Mount Sinai Hospital.

“Cardiovascular disease is the leading cause of death worldwide and early prevention is important for health gains and for cost reduction. I fully expect that individual awareness of cardiovascular disease based on imaging, accompanied by a comprehensive three-year work-based lifestyle intervention, will lead to a reduction in the prevalence of CV risk factors related to lifestyle,” said Fuster.

The population for the TANSNIP-PESA consists of people 40 to 60 years old and who are employees from a Spanish corporation. Employees will be divided into two groups. One group will comprise employees with high imaging-defined CV risk and a second group will comprise those with low imaging-defined CV risk. In both groups, participants will be randomized to either receive the comprehensive three-year worksite lifestyle intervention or standard occupational healthcare.

Employees in the workplace-based lifestyle intervention program will receive 12 personalized lifestyle counseling sessions spread over the three-year period, a Fitbit personal fitness monitor to self-monitor physical activity and an Ergotron sit-to-stand station. Data will be collected at baseline, at year one, at year two and at year three.

The primary outcome measure is the newly developed FUSTER-BEWAT score, which consists of blood pressure, physical activity, sedentary behavior, body mass index, fruit and vegetable consumption, and smoking. The researchers will also measure secondary outcomes such as changes in lifestyle, smoking, body weight, diet, vitality and quality of life, and risk factor profiles, as well as changes in blood biomarkers, and work-related outcomes such as work productivity and absenteeism.

The researchers hypothesize that the level of compliance with the lifestyle intervention will be higher in the group with high imaging-defined CV risk, compared to those with low imaging-defined CV risk. They will also review the cost-effectiveness of the intervention, compared with standard care, from both the societal and employer’s perspective.

This study is the first in a series of four known as the TANSNIP (Trans-Atlantic Network to Study Stepwise Noninvasive imaging as a Tool for Cardiovascular Prognosis & Prevention) Program. The four studies are designed to understand atherosclerosis in different populations, at different levels of risk and in different settings. The other TANSNIP studies include TANSNIP-H2H (heart to heart), which includes older patients and employs cutting-edge technology and cognitive dysfunction; TANSNIP–BioImage, which explores atherosclerosis progression in middle-aged people in Chicago and Florida; and TANSNIP-Genomics, which examines genomics, proteomics and metabolomics across the populations of the other three TANSNIP studies. TANSNIP seeks to develop lifestyle-changing tools based on non-invasive imaging results of subclinical atherosclerosis presence.

The TANSNIP-PESA project is an international initiative that is being conducted through partnerships with Centro Nacional de Investigaciones Cardiovasculares, the Icahn School of Medicine at Mount Sinai, the Framingham Heart Study, and the VU University Medical Center in Amsterdam.

The TANSNIP Program is funded by a $5 million grant from AstraZeneca.

For more information: www.mountsinaihealth.org

Related Content

Plant-Based Diets Benefit Athletes' Heart Health, Endurance, Recovery
News | Cardiac Diagnostics | January 21, 2019
Meat-free athletes have already proven the performance-boosting power of a plant-based diet. Now, “Plant-Based Diets...
Sedentary Lifestyle Cancels Out Heart Benefits of Normal Weight
News | Cardiac Diagnostics | January 09, 2019
January 9, 2019 — Researchers at the University of Florida have found that low levels of physical activity can put he
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Overlay Init